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Abstract Most patients with amyotrophic lateral sclerosis
(ALS) develop respiratory insufficiency in the advanced
stage of their disease. Non-invasive ventilation (NIV) is
commonly regarded to be a treatment that is effective in
reducing these complaints. To assess whether the effect of
NIV on gas exchange and quality of life (QOL) is different
in patients with ALS versus without ALS. A post hoc
analysis was done with data from a previously published
trial, in which all patients were instituted on NIV. Arterial
blood gasses were assessed next to QOL by generic as well
as disease-specific questionnaires. 77 patients started NIV:
30 with ALS and 47 without. Both groups showed signif-
icant improvements in blood gasses after 2 and 6 months.
Compared to the non-ALS group, the ALS group had
significantly worse scores after 6 months in MRF-28, SRI,
HADS and SF-36 than the non-ALS group. This study
shows that NIV improves gas exchange, both in patients
with and without ALS. QOL improves markedly more in
patients without ALS than in those with ALS, in whom
only some domains improve. Our observation of little or no
effect in ALS patients warrants a large study limited to
ALS patients only.
Keywords Amyotrophic lateral sclerosis  Quality of life 
Non-invasive ventilation
Introduction
Most patients with amyotrophic lateral sclerosis (ALS)
develop complaints of dyspnea, fatigue, unrefreshing sleep
and morning headache in the advanced stage of their dis-
ease due to respiratory insufficiency. Chronic ventilatory
support is commonly regarded to be a treatment that is
effective in reducing these complaints.
Several studies presented data regarding the effects of
chronic ventilatory support onquality of life (QOL) inpatients
with ALS. Some were positive, while others produced more
reservations regarding chronic ventilatory support in these
patients. In 2001, in a prospective study, QOL following non-
invasive ventilation (NIV) was assessed with two question-
naires, the ALS functional rating scale-respiratory version
(ALSFRS-R) and the Short Form 36 (SF-36) [1]. Early
intervention ofNIV resulted in an improved vitality compared
to standard care in this study. In 2003, Bourke et al. presented
the results of a cohort study on indications and effect of NIV
on QOL in ALS patients. They used the SF-36 to assess QOL
in 10 participants usingNIV. In this study, the use of NIVwas
associated with an improved QOL and survival [2]. Finally, a
third cohort study on the effects of NIV on ALS patients
showed that one month after starting chronic ventilatory
support, both blood gasses and QOL improved [3]. In 2006,
Bourke assessed the effect of NIV, QOL and survival in
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participants with ALS in a randomized controlled trial [4].
Their conclusion was that NIV use in patients without bulbar
dysfunction was associated with an improved QOL in some
domains and a longermaintainedQOLabove 75 %of the pre-
randomization QOL assessed by SF-36. Despite the results
mentioned above, Piepers et al. concluded in their review that
these studies on the use of NIV in patients with ALS differ
considerably in design and endpoint definitions and that well-
designed randomized controlled trials are, to their opinion, not
available [5].
We agree with the notion that more well-designed studies
are needed on the effect of chronic ventilatory support in
relation to QOL in patients with ALS. An additional point of
concern is that in most studies, only the generic SF-36 has
been used, while questionnaires set up specifically to assess
quality of life in patients with respiratory insufficiency like
the Maugeri Respiratory Failure (MRF-28) and the Severe
Respiratory Insufficiency (SRI)were not used at all. Also,we
believe that it is unfortunate that the previous studies did not
report on outcomes like depression and anxiety, items fre-
quently mentioned by patients with ALS.
In a randomized controlled study assessing the effect on
QOL of home versus in-hospital initiation of NIV in
patients with a neuromuscular disorder (NMD) or thoracic
cage problem, we showed an overall improvement of QOL
after the start of NIV [6]. However, in this study, the effect
size in separate diagnostic groups, such as ALS, was not
assessed. It was, however, unique in the sense that not only
the SF-36, but both the SRI and MRF-28 were used to
assess QOL, as was the Hospital Anxiety and Depression
Scale (HADS). By doing so, we created a broader per-
spective on QOL than with only the SF-36. In the present
analysis, we hypothesized that the effect of NIV on QOL in
patients with ALS, as assessed by the SF-36, SRI, MRF-28
and HADS questionnaires, is different compared to patients
with other reasons for need of NIV.
Methods
Apost hoc analysis was performed in all patients who started
with NIV, from a previously published randomized con-
trolled trial [6]. Patients, who had been diagnosed with
chronic respiratory failure due to a neuromuscular disorder
(NMD) or a thoracic cage problem,were included. The study
was approved by the Medical Ethics Committee of the
University of Groningen, University Medical Center of
Groningen, and written informed consent was obtained from
all patients. Chronic respiratory failure was defined as day-
time arterial carbon dioxide pressure (PaCO2) [6.0 kPa
([45 mmHg). Participants started NIV at home or in the
hospital in a randomized design. In line with our hypothesis
and reassuringly, the results for gas exchange and QOLwere
not significantly different between patients who started in the
hospital versus at home [7]. In the current analysis, we
pooled all patientswithoutALS in one group and compared it
to those with ALS. Gas exchange was assessed by daytime
arterial blood gasses from the radial artery, and the following
self-administered questionnaires were completed: SRI [8],
MRF-28 [9], the SF-36 [10] and the HADS [11]. The SRI
contains seven domains covering: respiratory complaints,
physical functioning, attendant symptoms and sleep, social
relationship, anxiety, psychological well-being and social
functioning. Scores range between 0 and 100,with high sores
representing better quality of life. The MRF-28 contains
three domains: daily activities, cognitive function and
invalidity; scores range from 0 (best) to 100 (worse). The SF-
36 contains eight domains: physical functioning, role phys-
ical, bodily pain, general health, vitality, social functioning,
role emotional and mental health completed with the phys-
ical and mental component summary score 0 (worse) to 100
(best) [12]. The HADS contains the anxiety and depression
domain; scores range from 0 (best) tot 42 (worse).
Statistical analyses
Independent-sample t tests were used to test for differences
in change (D) between groups from baseline to 6 months,
and paired sample t tests were performed to assess the
change within groups from baseline to 2 and 6 months. The
level of statistical significance was set at p\ 0.05. Statis-
tical analyses were performed using IBM Statistics 22
(IBM, New York, USA).
Results
77 participants were randomized to start NIV at home or in
the University Medical Center of Groningen (UMCG). For
this manuscript, both groups were pooled since there were
no differences between the results in both intervention
arms, as per prior hypothesis. Thirty participants had ALS
(grouped as ALS), the other 47 participants had a neuro-
muscular disease (diaphragm paralysis, myotonic dystro-
phy, limb girdle muscular dystrophy, facioscapulohumeral
dystrophy and other) or a thoracic cage problem
(kyphoscoliosis or obesity hypoventilation syndrome)
(grouped as non-ALS). The baseline characteristics are
presented in Table 1 and show that both groups were
comparable in age and gas exchange. NIV was initiated in
the ALS group a median of 427 (22–2582) days after being
diagnosed with ALS. Median survival in the ALS group
after the initiation of NIV was 461 (220–1451) days; none
of the participants was still alive at the moment of our
investigation. Eight patients in each group withdrew during
follow-up, mainly due to worsening of their disease, death
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or noncompliance with NIV [6]. Both groups showed an
improvement in arterial and transcutaneous CO2 and O2,
after 2 and 6 of NIV (Table 2); however, the mean
improvements in arterial and transcutaneous CO2 were not
significantly different between the groups. The mean
improvement in PaO2 after 6 months was significantly
lower in the non-ALS group compared to the ALS group.
The mean number of hours on NIV increased over time in
both groups. The ALS group used NIV for more than 11 h
after 6 months and the other group 8 h per day (between
group difference in change after 6 months p = 0.03). Some
patients used NIV 24 h per day, depending on the pro-
gression of their disease. Forced vital capacity (FVC)
showed a significant difference between both groups after
6 months as in the ALS group, the FVC decreased signif-
icantly, whereas the FVC in the non-ALS group improved
slightly (Table 2). At baseline, quality of life was higher in
the non-ALS group than in the ALS group. Compared to
the non-ALS group, the ALS group showed significantly
less improvement after 6 months on the MRF-28 total
score. (Fig. 1; Table 3). The sum score of the MRF-28,
SRI, HADS and SF-36 improved significantly in the non-
ALS group after 6 months, whilst in the ALS group, only
the sum score of theSF-36 improved significantly after
6 months (Table 3). QOL in the ALS group even deterio-
rated as expressed by the sum scores of the MRF-28, SRI
and HADS, leading to significant differences between
groups after 6 months.
Table 1 Baseline
characteristics
ALS group, n = 30 Non-ALS group, n = 47
Diagnosis Amyotrophic lateral sclerosis Neuromuscular disease (n = 42)
Thoracic cage problem (n = 5)
Age (years) 59.6 ± 10.6 57.7 ± 14.7
Male (%) 66.7 53.2
PaCO2 (kPa) 6.6 ± 0.8 6.6 ± 1.0
PaO2 (kPa) 10.4 ± 0.9 9.6 ± 1.6
BMI (kg/m2) 23.8 ± 5.2 28.9 ± 6.4
Packyears 27.8 ± 19.4 18.9 ± 14.4
Data are presented as mean ± standard deviation
kPa kilo Pascal, PaCO2 partial pressure of arterial carbon dioxide, PaO2 partial pressure of arterial oxygen,
BMI body mass index
Table 2 Changes in daytime arterial blood gasses, lung function, hours of non-invasive ventilation and transcutaneous carbon dioxide and
oxygen saturation after the start of non-invasive ventilation




















PaCO2 (kPa) 6.6 ± 0.8 -1.2 ± 0.4* -0.7 ± 0.3* 6.6 ± 1.0 -1.1 ± 0.2* -0.7 ± 0.2* 0.862
PaO2 (kPa) 10.4 ± 0.9 1.8 ± 0.7* 0.3 ± 0.4 9.6 ± 1.6 0.3 ± 0.7* 1.3 ± 0.3* 0.035
}
FVC (% pred) 41.6 ± 13.7 – -9.8 ± 3.7* 45.2 ± 16.6 – 2.5 ± 2.1 0.005}
FEV1 % FVC 88.1 ± 13.8 – -3.2 ± 3.4 76.2 ± 12.3 – 3.0 ± 2.9 0.247
NIV initiated,
N = 28
N = 27 N = 23 NIV initiated,
N = 46
N = 43 N = 42
Hours NIV 7.7 ± 3.8 3.5 ± 1.3* 3.8 ± 1.5* 6.8 ± 1.7 0.9 ± 0.4* 1.1 ± 0.4* 0.031
tcpCO2 (kPa) 6.5 ± 0.9 -1.6 ± 0.3* -2.5 ± 0.4 6.4 ± 0.9 -1.5 ± 0.2* -1.7 ± 0.3* 0.111
tcSpO2 (%) 95.9 ± 1.5 3.3 ± 0.4 3.8 ± 0.5* 95.1 ± 1.7 6.1 ± 1.0* 6.0 ± 1.1
* 0.103
Baseline data are presented as mean ± standard deviation
Changes over time are presented as mean ± standard error of mean
kPa kilo Pascal, PaCO2 partial pressure of arterial carbon dioxide, PaO2 partial pressure of arterial oxygen, FVC forced vital capacity, FEV1
forced expiratory volume in one second, %pred % predicted, NIV non-invasive ventilation, tcpCO2 transcutaneous carbon dioxide, tcSpO2
transcutaneous oxygen saturation
} p\ 0.05: for difference in change between groups 0–6 months
* p\ 0.05 for chances within groups from baseline
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Both groups showed significant improvements on the
attendant symptoms and sleep domain of the SRI which
improved significantly in both groups. Within the non-ALS
group, many domains improved significantly after both 2
and 6 months. By contrast, in the ALS group, only three
domains of the SRI improved significantly after 2 and
6 months; only the attendant symptoms and sleep domain
of the SRI were still significantly improved in the ALS
group as compared to baseline. Two domains of the SRI,
social functioning and social relationship, worsened sig-
nificantly in the ALS group, showing also a significant
difference between both groups.
Discussion
In this study, NIV was effective in improving gas exchange
in both the ALS and the non-ALS group after 2 and
6 months. While NIV also clearly improved QOL in the
non-ALS patients, the patients with ALS showed a
different pattern. After 2 months, only three domains of the
SRI questionnaire improved significantly. More impor-
tantly, quality of life became even worse in patients diag-
nosed with ALS as compared to the non-ALS group after
6 months of NIV.
More than 150 patients start chronic ventilatory support
every year at the Department of Home Mechanical Venti-
lation of our hospital. Patients visit the outpatient clinic
before starting chronic ventilatory support. Until now, we
advised ALS patients to start chronic ventilatory support
mainly based on the premise of a longer maintained QOL
or even improved QOL in the randomized controlled trial
of Bourke [13]. While different assessments on different
moments were used, our study showed that after 2 months
of NIV, QOL was maintained above 75 % of baseline in
both groups. After 6 months, the domains physical func-
tioning, role physical and role emotional of the SF-36 and
physical functioning and social functioning of the SRI were
under 75 % of baseline in the ALS group. Our group dif-
fers from that of Bourke et al., in that patients in the
Bourke study had higher vital capacity and lower starting
carbon dioxide at baseline compared to our study. In the
Bourke study, there was a mean of 710 days after the first
onset of weakness in any muscle before starting NIV. This
suggests a similar moment of starting NIV in both studies,
as the mean before the start of NIV in our study was
686 days. Our limited results in ALS were not the result of
a bulbar impairment as gas exchange improved, and more
importantly, only 2 out of 30 patients had a bulbar problem.
Most importantly, however, we have to take into account
that we did not include a control group with ALS but no
NIV in contrast to Bourke, and therefore, could not assess
if the NIV group was worse compared to a control group.
There were also important other differences between the
Bourke study and ours in the assessment of QOL. The SRI
and the MRF-28 questionnaires were specifically devel-
oped for patients with respiratory failure and, therefore,
used in our study, next to the HADS and SF-36. It is
remarkable to see that after 6 months of chronic ventilatory
support in the ALS group, only the SRI domain attendant
symptoms and sleep significantly improved. In contrast, the
sum score of the SRI, MRF-28 and HADS improved sig-
nificantly in the non-ALS group. We think that progression
of the disease ALS is one of the reasons that most domains
do not improve.
Routinely, during a house call visit after a patient with
ALS has died, we ask next of kin or caregivers to share
their experiences with us. In general, we are told they are
satisfied with the level of care and result of the therapy,
comfort during sleep and more awake during daytime.
However, during the last months of their life, these benefits
disappear as leakage of the mask during ventilation
becomes a burden for both the patient and relatives. The
ALS group




























Fig. 1 Quality-of-life measurement from baseline till 6 months after
the start of chronic ventilatory support. ALS amyotrophic lateral
scleroses, NIV non-invasive ventilation, SRI severe respiratory
insufficiency (0 = worst possible health; 100 = best possible health),
MRF-28 Maugeri Respiratory Failure (0 = best possible health;
100 = worst possible health), SF-36 Short-Form Health Status
Survey (0 = worst possible health; 100 = best possible health), SF-
36 PCS physical component score, SF-36 MCS mental component
score, HADS Hospital Anxiety and Depression Scale (0 = best
possible score; 48 = worst possible score)
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sound of air leaking by the mask and the ventilator wakes
everybody, and does not provide any comfort anymore. We
sometimes hear relatives make the remark that after the
patient has died, it was a relief to see them lying in bed
without mask and ventilatory support. These facts are
worthwhile to consider and should be shared with patients
before the start of HMV.
A limitation of our study is that it was primarily set up
as a randomized controlled trial, comparing initiation of
NIV at home with an in-hospital start irrespective of
diagnosis and, therefore, not to compare specifically ALS
to non-ALS patients. Comparing patients with and without
ALS is, from a life-expectancy perspective, imperfect and
should be done with caution. To understand the results of
Table 3 Changes in quality-of-life measurements after the start of non-invasive ventilation























Respiratory complaints 42.0 ± 16.8 6.7 ± 3.0* 2.0 ± 4.2 51.9 ± 19.5 9.7 ± 2.0 7.3 ± 2.0* 0.194
Physical functioning 21.0 ± 18.4 -3.0 ± 2.8 -7.9 ± 4.5 40.0 ± 19.7 2.9 ± 2.1 1.8 ± 3.0 0.075
Attendant symptoms/sleep 49.5 ± 14.6 15.2 ± 3.4* 15.6 ± 4.1* 53.3 ± 21.3 6.5 ± 2.3 11.4 ± 2.5* 0.363
Social relationship 68.2 ± 10.2 -0.6 ± 2.1 -6.3 ± 1.7* 70.9 ± 13.8 1.2 ± 2.0 1.3 ± 2.3 0.032}
Anxiety 47.4 ± 12.1 6.9 ± 2.7* -6.4 ± 4.2 59.5 ± 21.0 4.3 ± 2.5 9.0 ± 2.6* 0.002}
Well-being 51.2 ± 17.4 1.8 ± 2.6 0.4 ± 2.8 63.5 ± 16.6 1.0 ± 2.0 -0.1 ± 1.9 0.899
Social functioning 44.5 ± 13.7 -2.7 ± 2.5 -7.1 ± 3.0* 61.5 ± 18.0 1.4 ± 2.0 1.1 ± 2.1 0.027}
Summary score 46.3 ± 8.7 3.5 ± 1.8 -1.4 ± 2.4 57.2 ± 14.0 3.9 ± 1.3* 4.5 ± 1.6* 0.037}
MRF-28
Daily activities 74.0 ± 24.9 4.1 ± 2.4 5.4 ± 5.7 51.8 ± 29.2 -8.7 ± 3.6 -7.4 ± 4.3 0.083
Cognition 34.5 ± 33.0 -9.6 ± 6.2 -4.1 ± 6.2 37.8 ± 34.9 -9.7 ± 4.6* -7.6 ± 4.8 0.675
Invalidity 73.1 ± 31.7 -2.3 ± 6.0 2.7 ± 5.8 44.2 ± 35.1 -2.9 ± 5.0 4.2 ± 5.5 0.867
Total score 64.2 ± 17.9 -4.7 ± 2.4 -1.4 ± 4.2 50.2 ± 22.1 -13.0 ± 2.9* -11.9 ± 2.9* 0.041}
HADS
Depression 8.3 ± 7.2 -0.2 ± 0.6 1.0 ± 0.6 6.3 ± 3.8 -1.3 ± 0.4* -1.6 ± 0.4* 0.001}
Anxiety 7.3 ± 4.3 0.2 ± 0.6 0.8 ± 0.7 6.3 ± 4.0 -1.2 ± 0.5* -1.1 ± 0.4* 0.017}
Total score 15.6 ± 7.2 -0.0 ± 1.1 1.8 ± 1.1 12.6 ± 7.2 -2.5 ± 0.8* -2.7 ± 0.7* 0.001}
SF-36
Physical functioning 10.3 ± 17.6 -1.0 ± 1.4 -7.1 ± 3.2* 18.2 ± 21.5 4.0 ± 1.3* 4.4 ± 2.0* 0.002}
Role physical 6.0 ± 12.7 1.9 ± 4.6 -4.8 ± 3.3 19.7 ± 34.9 6.1 ± 6.0 17.4 ± 7.0* 0.036}
Bodily pain 66.9 ± 25.4 -3.8 ± 5.0 -11.4 ± 7.4 64.8 ± 32.5 -0.3 ± 4.4 3.0 ± 4.1 0.071
General health 19.6 ± 13.6 -0.3 ± 3.1 -3.0 ± 2.8 37.2 ± 22.4 2.5 ± 2.6 7.6 ± 3.1* 0.031}
Vitality 33.6 ± 17.3 3.1 ± 3.9 4.3 ± 4.0 40.4 ± 21.4 10.6 ± 3.1* 13.3 ± 2.7* 0.065
Social functioning 44.4 ± 27.7 2.9 ± 6.3 -13.6 ± 5.9* 59.8 ± 26.5 4.6 ± 3.7 11.3 ± 4.0* 0.001}
Role emotional 59.8 ± 45.7 -1.3 ± 12.8 -14.3 ± 8.5 46.1 ± 51.3 13.0 ± 9.4 20.9 ± 9.1* 0.017}
Mental health 64.4 ± 20.4 -0.5 ± 2.4 0.5 ± 3.2 66.2 ± 19.4 6.0 ± 2.0* 8.6 ± 2.5* 0.050
Physical component summary 25.7 ± 10.2 -0.8 ± 2.3 -6.8 ± 2.4* 34.5 ± 16.7 3.1 ± 2.1 8.1 ± 2.8* 0.001}
Mental component summary 49.4 ± 28.2 1.0 ± 7.6 -9.5 ± 5.3 47.2 ± 31.8 10.3 ± 5.6 16.6 ± 5.5* 0.004}
Baseline data are presented as mean ± standard deviation
Change over time are presented as mean ± standard error of mean
} p\ 0.05 for difference in change between groups 0–6 months
* p\ 0.05 for changes within groups from baseline
SRI Severe Respiratory Insufficiency (0 = worst possible health; 100 = best possible health), MRF-28 Maugeri Respiratory Failure (0 = best
possible health; 100 = worst possible health), HADS Hospital Anxiety Depression Scale (0 = best possible score; 42 = worst possible score),
SF-36 Short-Form Health Status Survey (0 = worst possible health; 100 = best possible health)
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the ALS group in a broader perspective, in a future study,
patients with ALS should be randomized to receive NIV or
not. However, starting a randomized controlled trial, one
group with NIV and one group without, is probably, from
an ethical perspective, not easy to realize, because NIV has
become the cornerstone of symptom management in
patients with ALS.
Second, the ALS group had a smaller size than the non-
ALS group resulting in lower chance of finding significant
within group results compared to the non-ALS group.
In conclusion, our study shows that NIV improves blood
gasses in a wide range of patients, with or without ALS.
However, in patients with ALS, QOL did not improve after
6 months of NIV relative to baseline, and some domains
(social functioning, social relationship and physical func-
tioning) even showed a significant deterioration compared
to baseline.
Given the doubt we create on the results of NIV in
patients with ALS, we believe that prospective studies are
warranted in ALS patients with proper randomized con-
trolled setup for this question, using disease-specific QOL
questionnaires.
With regard to the other studies, we think that in our
study, chronic ventilatory support was initiated in a more
advanced stage of the disease. Therefore, we believe that
these results raise questions about the efficacy of NIV in
these specific patients, but they need to be confirmed in a
future dedicated randomized controlled trial in ALS
patients using similar quality-of-life questionnaires.
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